Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.

Prior treatment

• Receiving systemic glucocorticoids, antibiotics, antifungals, immunomodulators, antihistamines and ultraviolet radiation therapy within the last 4 weeks before inclusion
• Receiving any topical AD-effective drugs within the last 2 weeks before inclusion

Other

• Patient candidates must not be enrolled in the study if they meet any of the following criteria:
• Patients for whom Elidel® is not recommended accordingly to the local Package Insert
• Patients with severe AD (SCORAD Index ≥50)
• Pregnant and/or breastfeeding women
• Patients or parent(s) / legal guardian (as applicable) that are not able to fulfil study requirements according to investigator's opinion
• Patients or parent(s) / legal guardian (as applicable) that refuse to participate to the study

• Patient eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before patients are included in the study.
  • Patients must meet all of the following inclusion criteria to be eligible for enrolment into the study:
• Patients that have been prescribed Elidel® according to the local Package Insert prior to and independently from patient's enrolment into the study.
• Patients of Asian ethnicity
• Patients within following age group for respective countries as defined below:
  • Malaysia: Patients \> 2 years and \<12 years old. Hong Kong: Patients \>3 months and \<12 years old. Thailand: Patients \>3 months and \<12 years old. Taiwan: Patients \>3 months and \<12 years old.
• Signed informed consent from patient and (as per local regulations) if applicable from parent(s) or legal guardian(s) in compliance with local requirements
• Patients with mild to moderate AD (SCORAD Index \<50)